Authorities will recommend puberty blockers as a treatment option for some transgender and gender-diverse children in Australia, despite increasing restrictions overseas and only limited evidence about their benefits and harms.
asserted
Authorities → recommend → benefits
The National Health and Medical Research Council (NHMRC) on Monday released interim guidance recommending puberty blockers can be considered for people under 18 who experience 'gender incongruence' - a mismatch between the sex a person was born into and the gender a person feels they are.
asserted
they → release → sex
Under 18s are eligible provided they have started puberty, have been assessed as suitable for treatment, and the decision is made jointly by the young person, their parents or carers, and clinicians.
asserted
decision → start → person
The advice, which is open for public consultation, is the first nationally endorsed clinical guidance on the issue in Australia and stands in contrast to moves in the UK and a growing number of US states to restrict access to the drugs.
asserted
which → endorse → drugs
Federal Health Minister Mark Butler on Monday said that the NHMRC’s recommendation was that puberty blockers could be used under strict safeguards in select cases.
uncertain
blockers → say → cases
'The National Health and Medical Research Council advice that was published... today suggests that puberty blockers or puberty suppressants can be used in certain circumstances and subject to a range of conditions,' he said.
'
uncertain
he → publish → conditions
Those conditions include, obviously, a process of shared decision making and consent by the young people, by clinicians, and importantly by parents.'
asserted
conditions → include → parents
Butler said any treatment would require a thorough health assessment, multidisciplinary input, and ongoing monitoring of patients.
asserted
treatment → say → patients
Mark Butler (pictured) said the federal government would not intervene on existing state laws.
asserted
government → picture → laws
Queensland and the Northern Territory have restricted access to puberty blockers
This new guidance follows the government’s 2025 decision to commission national guidelines for the care of trans and gender-diverse youth.
asserted
guidance → restrict → youth
Butler said the issue has become increasingly controversial since the publication of the independent Cass Review in the UK.
asserted
issue → say → UK
That review, commissioned by the UK's National Health Service and led by paediatrician Dr Hilary Cass, found the evidence supporting puberty blockers and cross-sex hormones for children and adolescents with gender distress was limited and of low quality.
asserted
evidence → commission → quality
The review found insufficient long-term evidence on the benefits, risks, and outcomes of the treatments, leading to calls for a more cautious, evidence-based approach.
asserted
review → find → approach
The United States, meanwhile, remains deeply divided.
asserted
States → remain → ?
While puberty blockers remain legal in all 50 states for non-transgender medical conditions, 24 states now have restrictions or bans on their use for transgender minors.
asserted
states → remain → minors
It follows major legislative changes and the US Supreme Court’s 2025 United States v Skrmetti decision, which upheld states’ rights to restrict gender-affirming treatments for children.
asserted
which → follow → children
'This is, I think it’s fair to say, an area of clinical practice that attracts a lot of public commentary and public debate, and that is understandable given we’re talking about children and adolescents, particularly children and adolescents who are often quite vulnerable,' Butler said.
asserted
Butler → think → children
The NHMRC classified its recommendation as ‘conditional’, acknowledging the evidence for the benefits and risks of puberty blockers remains limited and that all treatment decisions should be made individually.
asserted
decisions → classify → blockers
The NHMRC recommended puberty blockers to be considered for people under 18 who have 'gender incongruence' (file photo of transgender flag above)
The advice may put pressure on Queensland and the Northern Territory, both of which have restricted access to puberty blockers and gender-affirming hormones through their public health systems.
uncertain
both → recommend → systems
In Queensland, a ministerial direction from the Crisafulli Government prevents public hospitals from starting new under-18s on puberty blockers or gender-affirming hormones for gender dysphoria.
asserted
direction → prevent → dysphoria
Young people already receiving treatment before Queensland’s 2025 freeze can continue, and puberty blockers remain available for non-transgender medical conditions such as precocious puberty.
asserted
blockers → receive → puberty
The Queensland Government has extended its ban until 2031, to coincide with the conclusion of the UK’s PATHWAYS clinical trial, which is examining the safety and effectiveness of puberty blockers.
asserted
which → extend → blockers
The Northern Territory has also halted new publicly funded prescriptions of puberty blockers and gender-affirming hormones for under-18s, though mental health support remains available and private doctors may still prescribe the medicines.
uncertain
doctors → halt → medicines
Asked whether those governments should reverse their bans, Butler stopped short of demanding change.
asserted
Butler → ask → change
'I know traditionally state governments of both political persuasions have always paid high regard to the advice of the National Health and Medical Research Council,' he said.
asserted
he → know → Council
The Crisafulli Government moved to ban puberty blockers in public clinics until 2031
Nationally, puberty blockers are still legal and can be prescribed by Australian clinicians.
asserted
blockers → move → clinicians
They are generally provided on an off-label basis and are not subsidised through the Pharmaceutical Benefits Scheme for gender-related treatment.
asserted
They → provide → treatment